Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph early_phase_1
1
25%
Ph phase_3
1
25%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Other(4)

Detailed Status

unknown4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (50.0%)
Phase 31 (50.0%)

Trials by Status

unknown4100%

Recent Activity

0 active trials
Showing 4 of 4
unknownphase_3

Imatinib in Acute Ischaemic Stroke

NCT03639922
unknown

To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.

NCT03424876
unknown

Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation

NCT03381053
unknownearly_phase_1

Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

NCT03228303

Clinical Trials (4)

Showing 4 of 4 trials
NCT03639922Phase 3

Imatinib in Acute Ischaemic Stroke

Unknown
NCT03424876

To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.

Unknown
NCT03381053

Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation

Unknown
NCT03228303Early Phase 1

Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4